- Home
- ARGX vs DDOG Comparison
ARGX vs DDOG Comparison
Compare ARGX & DDOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- DDOG
- Stock Information
- Founded
- ARGX 2008
- DDOG 2010
- Country
- ARGX Netherlands
- DDOG United States
- Employees
- ARGX N/A
- DDOG N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- DDOG Computer Software: Prepackaged Software
- Sector
- ARGX Health Care
- DDOG Technology
- Exchange
- ARGX Nasdaq
- DDOG Nasdaq
- Market Cap
- ARGX 35.3B
- DDOG 35.1B
- IPO Year
- ARGX 2017
- DDOG 2019
- Fundamental
- Price
- ARGX $573.26
- DDOG $117.88
- Analyst Decision
- ARGX Strong Buy
- DDOG Buy
- Analyst Count
- ARGX 20
- DDOG 33
- Target Price
- ARGX $698.22
- DDOG $142.67
- AVG Volume (30 Days)
- ARGX 493.8K
- DDOG 5.0M
- Earning Date
- ARGX 05-08-2025
- DDOG 05-06-2025
- Dividend Yield
- ARGX N/A
- DDOG N/A
- EPS Growth
- ARGX N/A
- DDOG 45.28
- EPS
- ARGX 15.94
- DDOG 0.47
- Revenue
- ARGX $2,643,062,000.00
- DDOG $2,834,575,000.00
- Revenue This Year
- ARGX $61.64
- DDOG $22.86
- Revenue Next Year
- ARGX $32.00
- DDOG $18.80
- P/E Ratio
- ARGX $32.97
- DDOG $248.64
- Revenue Growth
- ARGX 82.13
- DDOG 25.54
- 52 Week Low
- ARGX $359.37
- DDOG $81.63
- 52 Week High
- ARGX $678.21
- DDOG $170.08
- Technical
- Relative Strength Index (RSI)
- ARGX 45.96
- DDOG 63.90
- Support Level
- ARGX $570.00
- DDOG $113.30
- Resistance Level
- ARGX $584.90
- DDOG $118.72
- Average True Range (ATR)
- ARGX 14.55
- DDOG 2.64
- MACD
- ARGX 0.82
- DDOG -0.07
- Stochastic Oscillator
- ARGX 66.03
- DDOG 82.23
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
About DDOG Datadog Inc.
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered via software as a service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of applications throughout their businesses.